Compare Commvault Systems Inc (CVLT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Moderna, Inc. — how do they compare? Commvault Systems Inc trades at $140.14 (market cap $5.78B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 4.2× Commvault Systems Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Commvault Systems Inc nearer its low. Which is the better fit depends on your goals.
| CVLT | MRNA | |
|---|---|---|
Market Cap | $5.78B | $24.18B |
Sector | Technology | Health |
52-Week High | $195.41 | $81.80 |
52-Week Low | $75.18 | $22.36 |
Enterprise Value | $5.76B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $139.36, down slightly by 0.05% on the day, with strong technical momentum showing a bullish moving average signal. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $1.42 surpassing the $1.16 estimate. Recent positive developments include the integration of Threat Scan with Google Threat Intelligence and a partnership with Microsoft for AI security on Azure, driving investor optimism despite a shareholder investigation announcement.
CVLT presents a mixed fundamental picture with robust revenue growth and strong profitability metrics but elevated valuation multiples. The stock offers significant upside to the consensus price target of $172.40, supported by 54.5% analyst buy ratings. Key risks include high P/E ratio of 89.35, ongoing fiduciary investigation, and potential margin compression as revenue growth outpaces net income growth in 2026 projections.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
